GET FREE SAMPLEMosapride citrate dihydrate CAS 156925-25-6
Specification:
| Item | Specifications |
| Description | White to yellowish crystal powder |
|
Identification |
Chemical reaction: show a positive reaction of Citrate |
| UV: the spectrum is consistent with the reference at the samewavelenths | |
| IR: the spectrum is consistent with the reference | |
| Water | 5.0-6.5% |
| Fluorine | 2.6-3.2% |
| Chloride | NMT 0.01% |
| Sulfate | NMT 0.08% |
| Heavy metals | NMT 20 ppm |
| Residue on ignition | NMT 0.1% |
| Related substances | Total : 0.5% max |
| Single :0.1%max | |
|
Solvent |
Ethanol: NMT 0.5% |
| Methanol: NMT 0.3% | |
| Dichloromethane :NMT 0.06% | |
| Chloroform : NMT 0.006% | |
| Toluene :NMT 0.089% | |
| Assay | 98.5%-101.0% |
Application Usage:
Mosapride citrate dihydrate CAS 156925-25-6 Mosapride Citrate (MC) is a fourth-generation gastrointestinal prokinetic drug and a potent, selective 5-HT4 receptor agonist. It stimulates 5-HT4 receptors in the myenteric plexus, stimulating acetylcholine release and enhancing gastric and duodenal motility. It is clinically indicated for conditions such as functional dyspepsia, gastroesophageal reflux disease, diabetic gastroparesis, and gastric dysfunction in patients undergoing partial gastrectomy. Common adverse reactions include diarrhea, abdominal pain, dry mouth, rash, malaise, and headache. Currently, the market only offers oral dosage forms such as tablets, dispersible tablets, and capsules.
Mosapride citrate dihydrate CAS 156925-25-6
Package and Shipping:
1kg/package or as customer request
Mosapride citrate dihydrate CAS 156925-25-6
Storage:
Cool and dry place .
